

## Dupixent

Oman · access guide

# How to access Dupixent from Oman, the named-patient import pathway, 2026

By Reserve Meds, Clinical and regulatory team. Last reviewed 2026-05-13.

An Omani patient with moderate-to-severe atopic dermatitis, moderate-to-severe asthma with type 2 inflammation or oral corticosteroid dependence, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease with type 2 inflammation may receive a prescription for Dupixent (dupilumab) from their treating allergist, dermatologist, or pulmonologist depending on indication. Dupixent is FDA-approved in the United States and manufactured by Regeneron Pharmaceuticals and Sanofi. It is a fully human IL-4 receptor alpha antagonist monoclonal antibody administered by subcutaneous injection. Local availability of Dupixent in Oman can be inconsistent: the drug may not be on every specialty pharmacy's standing formulary, the specific indication may not match what is locally registered, or the strength required may be back-ordered. When that happens, a named-patient import pathway through MoH Oman remains a legitimate route for the patient whose physician has already prescribed the drug.

This guide explains the pathway, the documentation your physician needs, typical costs and indicative timing, and where Reserve Meds fits in.

## The clinical situation

Dupixent is a fully human IL-4 receptor alpha antagonist monoclonal antibody. Mechanism: a fully human IgG4 monoclonal antibody that binds IL-4Ralpha and blocks IL-4 and IL-13 signaling driving type 2 inflammation. Dosing: loading and maintenance subcutaneous dosing varies by indication (for atopic dermatitis: 600 mg loading then 300 mg every 2 weeks in adults), per FDA labeling. Baseline workup per FDA labeling includes baseline eosinophil count, atopic and asthma history, infection screen, and helminth infection assessment in endemic regions. Other important warnings include hypersensitivity including anaphylaxis, conjunctivitis and keratitis (in atopic dermatitis), eosinophilic conditions, and helminth infection precautions. Your specialist will discuss the risk-benefit profile and schedule monitoring before initiating therapy.

## Is Dupixent legally importable into Oman?

Yes, through the Oman Ministry of Health (MoH) named-patient and personal-use import framework, coordinated with the treating facility's pharmacy. Oman has an established pathway for specialty medicines approved by reference authorities (US FDA, EMA, MHRA) but not stocked or registered for the specific indication locally.

The MoH Oman named-patient route allows an Omani-licensed physician to request import of a medicine when: (a) the medicine is approved by a recognised reference authority, (b) no clinically equivalent locally registered alternative is suitable for the patient's indication and history, (c) the treating physician takes clinical responsibility for use, and (d) chain of custody is documented from the US source to the administering facility. Applications are typically filed through the dispensing institution's import pharmacy on the physician's behalf, with approval issued on a per-patient, per-cycle quantity basis.

## How the pathway works, step by step

---

1. **Consultation with your treating specialist.** The prescribing decision is clinical. Your specialist documents the indication, prior therapies where relevant, and rationale for Dupixent.
2. **Baseline screening.** Baseline eosinophil count, atopic and asthma history, infection screen, and helminth infection assessment in endemic regions are confirmed and documented.
3. **MoH Oman named-patient application.** Your specialist or the facility's import pharmacy files the application with clinical rationale, patient reference, product strength, quantity requested, and chain-of-custody plan.
4. **US-side sourcing.** Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from Regeneron Pharmaceuticals and Sanofi's authorised distribution under DSCSA chain-of-custody.
5. **Cold-chain shipment.** Dupixent requires refrigerated transport at 2 to 8 degrees Celsius. Shipments include temperature-monitored packaging with continuous loggers and tamper-evident seals.
6. **Arrival and first dose.** The dispensing pharmacy releases product against the physician's prescription, and your specialist initiates therapy.

## What documentation your physician needs

---

Your physician will typically need to provide:

- A clinical rationale letter confirming diagnosis, prior therapies where relevant, and Dupixent as the indicated next step
- Verification of their Omani medical licence
- A patient identifier, anonymised reference where privacy is preferred
- Documented pre-treatment screening consistent with FDA labeling (see above)
- The planned dosing regimen (loading and maintenance subcutaneous dosing varies by indication (for atopic dermatitis: 600 mg loading then 300 mg every 2 weeks in adults), per FDA labeling)
- A monitoring plan covering baseline eosinophil count, helminth screen where relevant, and indication-specific dosing schedule

Reserve Meds provides a physician documentation kit tailored for IL-4Ralpha biologic therapies, including the templates MoH Oman reviewers commonly request.

## Typical costs and indicative timing

---

Reserve Meds gives you a drug-only reference range plus a transparent delivered quote at intake. As an illustrative composite case, the US cash-pay reference range for a typical month of every-2-week dosing of Dupixent sits in an indicative 2026 band of approximately USD 3,500 to 4,500. International logistics, MoH Oman documentation handling, cold-chain shipping, and concierge coordination add incremental cost. The delivered quote we issue at intake shows each line separately.

Indicative timing for first dose after cohort intake opens is approximately 2 to 5 weeks from the moment a complete application is submitted, assuming the documentation package is clean on first pass. Refills ship on a rolling cadence aligned to the dosing schedule.

Service availability is limited to our first cohort. All timelines are indicative, not guarantees.

## Where Reserve Meds fits in

---

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Dupixent specifically, we provide:

- **Sourcing.** Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody from manufacturer to export.
- **Documentation.** Regulatory package tailored for your physician and for MoH Oman review, including IL-4Ralpha biologic class templates.
- **Cold-chain logistics.** Temperature-monitored, internationally tracked shipment to your named dispensing facility with continuous temperature loggers.
- **Concierge case lead.** A named point of contact for your family and your physician across the full case arc.

We are a coordinator. We are not the prescriber, not a pharmacy, and not a dispensing facility. All clinical decisions remain with your treating specialist, and dispensing sits with the licensed Omani pharmacy of record. Reserve Meds operates on cash-pay only and does not bill insurance.

## Frequently asked

---

**Is this legal in Oman?** Yes, when executed through the MoH Oman named-patient and personal-use framework with appropriate documentation, clinical rationale, and a licensed dispensing facility. The pathway is routinely used across oncology, rare disease, and immunology at Omani tertiary centers.

**Will my private health insurance cover this?** Cash-pay is the default posture. Cash-pay is the default posture in Oman; some private plans cover specialty imports case-by-case. We supply documentation for your submission but do not process insurance claims.

**How does cold-chain affect timing?** Dupixent ships refrigerated. We use validated packaging with continuous temperature monitoring, and arrival temperature data is logged on every shipment.

**What if my physician has not filed a named-patient request before?** Named-patient import is an institutional process most major Omani tertiary centers (Sultan Qaboos University Hospital, the Royal Hospital, and Khoula Hospital) have encountered. Our documentation kit is written for first-time applicants and tracks what MoH Oman reviewers commonly ask for.

## ***Reserve Meds's role***

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

---

### **Reserve Meds**

*reserved for you.*

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.

reservemeds.com · hello@reservemeds.com